|
Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes
|
Jul 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate
|
Jan 2017
|
Expert Rev Hematol
|
myelodysplastic syndromes (MDS)
|
|
Decreased plasma cytokines associate with low platelet counts in aplastic anemia and immune thrombocytopenic purpura
|
Apr 2012
|
J Thromb Haemost
|
|
|
Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria
|
Sep 2014
|
J Clin Invest
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Defeating anaemia in myelodysplastic syndromes: another step forward
|
Sep 2017
|
Lancet Oncol
|
myelodysplastic syndromes (MDS)
|
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms
|
Jul 2019
|
Surgical Pathology Clinic
|
myelodysplastic syndromes (MDS)
|
|
Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
|
Jun 2013
|
Immunotherapy
|
myelodysplastic syndromes (MDS)
|
|
Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes
|
Jun 2016
|
Hematology
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes
|
Mar 2015
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
